PD-L1, PD-1, and CTLA-4 as prognostic biomarkers in resected non-small cell lung cancer.
Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Gabriel Sica(Emory University), William Mayfield(WellStar Health System), Lieping Chen(Yale Cancer Center), Bhakti Dwivedi(Emory University), Zhengjia Chen(Hunan University of Traditional Chinese Medicine), Fadlo R. Khuri(American University of Beirut Medical Center), Suresh S. Ramalingam(Emory University), Sungjin Kim(Cedars-Sinai Medical Center), Madhusmita Behera(National Institutes of Health), Robert C. Hermann(WellStar Health System), Jeanne Kowalski(The University of Texas at Austin)
Cited by 3
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k